Acquired Idiopathic ADAMTS13 Activity Deficient Thrombotic Thrombocytopenic Purpura in a Population from Japan

被引:51
|
作者
Matsumoto, Masanori [1 ]
Bennett, Charles L. [2 ,3 ]
Isonishi, Ayami [1 ]
Qureshi, Zaina [2 ,3 ]
Hori, Yuji [1 ]
Hayakawa, Masaki [1 ]
Yoshida, Yoko [1 ]
Yagi, Hideo [1 ]
Fujimura, Yoshihiro [1 ]
机构
[1] Nara Med Univ, Dept Blood Transfus Med, Kashihara, Nara 634, Japan
[2] Univ S Carolina, S Carolina Coll Pharm, S Carolina Ctr Econ Excellence Medicat Safety & E, Columbia, SC 29208 USA
[3] Univ S Carolina, S Carolina Coll Pharm, So Network Adverse React SONAR, Columbia, SC 29208 USA
来源
PLOS ONE | 2012年 / 7卷 / 03期
关键词
VON-WILLEBRAND-FACTOR; FACTOR-CLEAVING PROTEASE; PLASMA-EXCHANGE; UREMIC SYNDROME; MICROANGIOPATHIES; ANTIBODIES; FEATURES; COHORT; TITER;
D O I
10.1371/journal.pone.0033029
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Thrombotic thrombocytopenic purpura (TTP) is a type of thrombotic microangiopathy (TMA). Studies report that the majority of TTP patients present with a deficiency of ADAMTS13 activity. In a database of TMA patients in Japan identified between 1998 and 2008, 186 patients with first onset of acquired idiopathic (ai) ADAMTS13-deficient TTP (ADAMTS13 activity <5%) were diagnosed. The median age of onset of TTP in this group of patients was 54 years, 54.8% were female, 75.8% had renal involvement, 79.0% had neurologic symptoms, and 97.8% had detectable inhibitors to ADAMTS13 activity. Younger patients were less likely to present with renal or neurologic dysfunction (p < 0.01), while older patients were more likely to die during the TTP hospitalization (p < 0.05). Findings from this cohort in Japan differ from those reported previously from the United States, Europe, and Korea with respect to age at onset (two decades younger in the other cohort) and gender composition (60% to 100% female in the other cohort). We conclude that in one of the largest cohorts of ai-TTP with severe deficiency of ADAMTS13 activity reported to date, demographic characteristics differ in Japanese patients relative to those reported from a large Caucasian registry from Western societies. Additional studies exploring these findings are needed.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura
    Bendapudi, Pavan K.
    Foy, Brody H.
    Mueller, Sarah B.
    Liu, Jun
    Feingold, Louis M.
    Burke, Kristen E.
    Cruz, Wendy
    Chen, Maria Y.
    Lau, Emily S.
    Goldberg, Rachel L.
    Tatake, Ishan
    Wilkinson, Shelby C.
    Carney, Brian J.
    Stone, James R.
    Park, Doyun
    Avelino, Alzira R.
    Hassan, Sajjad
    Andrzejewski, Chester
    Ruby, Kristen N.
    Friedman, Kenneth D.
    Brunker, Patricia A. R.
    Leaf, Rebecca K.
    Higgins, John
    Dzik, Walter H.
    Stefely, Jonathan A.
    Makar, Robert S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (18): : 1690 - 1698
  • [22] Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura
    Wendt, Ralph
    Voelker, Linus A.
    Brinkkoetter, Paul T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (04): : 382 - 384
  • [23] Recombinant ADAMTS13 for Hereditary Thrombotic Thrombocytopenic Purpura
    Lorenz, Judith
    ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE, 2024, 228 (05): : 410 - 411
  • [24] ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy
    Raman, Rachna
    Yang, Shangbin
    Wu, Haifeng M.
    Cataland, Spero R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (02) : 277 - 278
  • [25] Thrombotic Thrombocytopenic Purpura: Relationship of Infection and ADAMTS13
    Watanaboonyongcharoen, P.
    Brecher, M. E.
    Schultz, E. F.
    Hay, S. N.
    Park, Y. A.
    TRANSFUSION, 2012, 52 : 126A - 127A
  • [26] Recombinant ADAMTS13 for Hereditary Thrombotic Thrombocytopenic Purpura
    Asmis, Lars M. M.
    Serra, Andreas
    Krafft, Alexander
    Licht, Abraham
    Leisinger, Elke
    Henschkowski-Serra, Jana
    Ganter, Michael T. T.
    Hauptmann, Steffen
    Tinguely, Marianne
    Hovinga, Johanna A. Kremer A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (25): : 2356 - 2361
  • [27] Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura
    Cataland, Spero R.
    Wu, Haifeng M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (04) : 437 - 444
  • [28] Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura
    Scully, Marie
    Antun, Ana
    Cataland, Spero R.
    Coppo, Paul
    Dossier, Claire
    Biebuyck, Nathalie
    Hassenpflug, Wolf-Achim
    Kentouche, Karim
    Knoebl, Paul
    Kremer Hovinga, Johanna A.
    Lopez-Fernandez, M. Fernanda
    Matsumoto, Masanori
    Ortel, Thomas L.
    Windyga, Jerzy
    Bhattacharya, Indranil
    Cronin, Michael
    Li, Hong
    Mellgard, Bjorn
    Patel, Munjal
    Patwari, Parth
    Xiao, Shan
    Zhang, Pinghai
    Wang, Linda T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (17): : 1584 - 1596
  • [29] ADAMTS13 Activity and Autoantibodies Subclasses as Recurrency Risk Predictors In Acquired Thrombotic Thrombocytopenic Purpura.
    Bettoni, Giuseppe
    Lotta, Luca A.
    Consonni, Dario
    Motti, Dino F. A.
    Palla, Roberta
    Valsecchi, Carla
    Casoli, Gloria
    Rovati, Andrea
    Pizzuti, Michele
    Peyvandi, Flora
    BLOOD, 2010, 116 (21) : 1049 - 1049
  • [30] CLINICAL FEATURES OF PATIENT WITH SEVERE ACQUIRED ADAMTS13 DEFICIENCY IN THROMBOTIC THROMBOCYTOPENIC PURPURA
    Oh, D.
    Kim, I. -H.
    Jung, C. -W.
    Le, J-W.
    Lee, H. G.
    Sohn, S. K.
    HAEMATOLOGICA, 2015, 100 : 565 - 565